Zaven Kaprielian

Zaven is Chief Scientific Officer of Remix Therapeutics. He brings extensive research and drug discovery experience, as well as deep domain expertise in Neuroscience to the team. Most recently, he was a venture partner at the Dementia Discovery Fund managed by SV Health Investors, where he focused on company creation. Prior to that he was a director of neuroscience research at Amgen in Cambridge, MA, and managed teams tasked with developing new therapeutics for neurodegenerative disorders and chronic pain. Before joining industry, he was a faculty member at the Albert Einstein College of Medicine directing a research group investigating the molecular mechanisms underlying axon guidance and dendrite branching in the developing spinal cord and brain. Zaven received his PhD from The Johns Hopkins University and carried out postdoctoral training at the California Institute of Technology. He is excited about Remix’s unique approach of manipulating RNA processing for therapeutic benefit in a variety of indications.